The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial evaluated anti-IL-1β to treat atherosclerosis, and results indicated that treatment significantly reduced lung cancer incidence [97,103]. The gene discussed is IL1B; the disease is lung carcinoma.